About Us WHAT WE DO Elusys is a private commercial-stage biopharmaceutical company that has achieved US, Canada, United Kingdom and European Union licensure for its lead antibody therapeutic, a medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack. ANTHIM® has been delivered to the US Strategic National Stockpile as the result of a successful, multi-year partnership with the US government. OUR PRODUCTS Visit Anthim.com ANTHIM® (obiltoxaximab) Elusys has been awarded over $320 million in procurement and development contracts by the Biomedical Advanced Research and Development Authority (BARDA), the National Institute of Allergy and Infectious Disease (NIAID) and the Department of Defense (DoD). Working closely with these agencies, Elusys has been able to advance ANTHIM to the commercial stage providing a therapeutic for inclusion in the Strategic National Stockpile to strengthen US biosecurity against a potential anthrax attack. ANTHIM was licensed for commercial use by the FDA in 2016. In addition to government contracts and grants, Elusys has received funding from a prestigious group of biotech investors, including Essex Woodlands Healthcare, Medimmune Ventures, Invesco Pfizer and Crescendo Ventures. US/CA: ANTHIM® (obiltoxaximab) US Prescribing Information Canadian Monograph (English) Canadian Monograph (French) EU/UK*: Obiltoxaximab SFL Summary of Product Characteristics (SmPC) (EN) *SFL Pharmaceuticals Deutschland GmbH is the EU Marketing Authorization Holder LEADERSHIP Elusys’ management team has decades of experience in the biopharmaceutical industry, which includes management of multiple US government contracts and deep experience in developing late-stage product candidates. Executive Team Elizabeth Posillico, PhD President and Chief Executive Officer Robin Conrad, MS Vice President, Regulatory Affairs Jeremy Middleton Vice President, Corporate Development James Porter, MS Vice President, Development and Manufacturing Vera Wong, MBA, CPA Vice President, Finance Board of Directors Ron Eastman Chairman of the Board Benjamin Gruder Managing Director, Invesco Private Capital Jeffrey Wolf Founder, CEO and Chairman, Heat Biologics, Inc. Elizabeth Posillico, PhD President and Chief Executive Officer, Elusys . OUR PARTNERS About Us What We Do Our Products Leadership Executive Team Board of Directors Our Partners About Anthrax What is anthrax? The threat of anthrax Transmission and spread of anthrax Symptoms of inhalation anthrax Anthrax Treatment Media Center Press Releases Resources and Links Publications Contact Us Site Map Privacy Terms And Conditions Copyright 2021 Elusys Therapeutics, Inc. All Rights Reserved.